Who
Suma Krishnan
President, R&D
Company insider
Files Form 4 as: President, R&D, Krystal Biotech; SVP--Product Development, Precigen; Vice President, Product Dev., New River Pharmaceuticals.
In numbers
- Trades disclosed
- 379
- Buys
- 5
- Sells
- 46
- Bought
- $2.1M
- Sold
- $168.6M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 29 Mar 2005
- Last trade
- 4 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $184K520 at $354.54 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $205K565 at $363.34 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $484K1,329 at $364.48 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $302K826 at $365.41 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $146K399 at $366.56 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $713K2,006 at $355.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,267 at $356.37 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.4M3,962 at $357.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.1M3,180 at $358.42 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,392 at $359.39 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $836K2,320 at $360.47 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $449K1,242 at $361.61 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $722K1,992 at $362.65 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $184K520 at $354.54 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $713K2,006 at $355.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,267 at $356.37 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.4M3,962 at $357.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.1M3,180 at $358.42 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,392 at $359.39 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $836K2,320 at $360.47 | filing |
News
Monte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head SurveyKRYS · tickerreport.com · 21 Oct 2026Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock UpKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin SyndromeKRYS · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name Suma Krishnan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.